Every senolytic claim runs into the same problem: senescent cells sit inside tissues, and nobody is going to biopsy your kidney to see whether a supplement worked. A test that could count senescent cells in an ordinary blood sample would change that, and a 2024 study in Aging Cell is one of the most serious attempts so far [1].
It is also one of the few human data points with fisetin in it. Buried in the abstract is a sentence that matters to anyone taking fisetin: the senescence signal was lower in a small subgroup of participants who were taking it. That sentence needs reading carefully, and this page does that.
Key Takeaways
- Researchers used a fluorescent probe, C12FDG, to measure the share of senescent white blood cells in a large group of healthy people and people with osteoarthritis [1].
- The share rose with age, tracked other senescence-related blood markers, and was higher in mild to moderate osteoarthritis.
- In a small subgroup taking fisetin, both the C12FDG signal and age-related serum markers were lower. The abstract gives no number, dose or control group for them.
- It is a promising measuring tool, not proof that fisetin clears senescent cells in people.
Important: This article describes research on a laboratory test and is not medical advice. C12FDG testing is a research method, not a routine clinical blood test. Fisetin has not been shown to slow aging or treat osteoarthritis in humans, and it can interact with prescription medicines. Speak to a doctor or pharmacist before taking it.
What C12FDG actually measures
Senescent cells have stopped dividing but stay metabolically active and release inflammatory signals, a cocktail known as the senescence-associated secretory phenotype [1]. One of the oldest ways to spot them is raised activity of an enzyme, senescence-associated beta-galactosidase. C12FDG is a compound that becomes fluorescent when that enzyme cuts it, so senescent-looking cells light up and can be counted one at a time by flow cytometry.
The study applied this to peripheral blood mononuclear cells, the lymphocytes and monocytes in an ordinary blood draw, including T cells [1]. The authors note that higher numbers of senescent blood cells have already been linked with frailty, rheumatoid arthritis and bone loss. The open question was whether the measurement could be useful in orthopaedics, where age-related joint decline is common and hard to predict.
What the study found
Across a large cohort of healthy and osteoarthritic patients, the percentage of C12FDG-positive blood cells increased with age, and it rose in step with other senescence-related serum biomarkers [1]. That agreement matters: a new marker is more believable when it moves with independent measures of the same process.
C12FDG-positive blood cells and T cells were also elevated in people with mild to moderate osteoarthritis, a joint disease strongly associated with inflammation [1]. The authors propose that these measurements could feed a composite score of healthy aging sensitive enough to detect changes after senolytic therapy, and might help predict orthopaedic decline. That is a proposal, not a validated clinical use. Our page on fisetin and osteoarthritis covers why senescent cells are suspected in joint disease.
The fisetin sentence, read carefully
The abstract says that the percentage of C12FDG-positive blood cells and the age-related serum biomarkers were decreased in a small subgroup of study participants taking the senolytic drug fisetin [1]. That is the whole of what it says.
Several things a reader would want are not in that sentence. It does not say how many people were in the subgroup, what dose they took, for how long, or whether they were assigned to fisetin or were simply people who happened to take it. It does not describe a placebo group. Read at face value, this is an observation inside a cohort study, not a randomised comparison.
That distinction matters because people who choose to take a longevity supplement may differ from those who do not in age, health, exercise and diet, any of which could also move a senescence marker. The finding is worth having. It is a reason to run a proper trial with this measurement, not evidence that fisetin cleared senescent cells in those participants.
Why a blood marker matters for fisetin research
Fisetin’s reputation rests mostly on animal work. In mice, it reduced senescence markers in multiple tissues and extended lifespan when given late in life [2]. Human trials have been slower to report, partly because it is hard to pick an outcome that shows a senolytic is doing its job within weeks.
Trial designs have reached for different markers. A planned triple-blind trial of 100 mg a day uses suPAR, a general marker of chronic inflammation, as its main outcome [3]. A trial in nursing-home residents with COVID-19 was built around the idea that fisetin could reduce the inflammatory output of senescent cells during infection [4]. A 2026 review notes that fisetin has reduced circulating secretory-phenotype factors in early studies [5]. None of these counts senescent cells directly. A validated C12FDG count would let trials ask the more direct question of whether there are fewer senescent cells afterwards.
Our page on the AFFIRM-LITE frailty trial describes one of the larger human studies, and fisetin and immune aging explains why senescent T cells are a target in their own right.
Can you get this test?
Not as a routine lab order. C12FDG flow cytometry is a research method, and the study’s own framing is that it may become clinically useful, not that it already is [1]. A result from one blood draw would also be hard to interpret without the reference ranges that a validated clinical test provides.
If you want to track something while trying fisetin, the practical options are standard inflammation and metabolic markers that any lab can run. Our guide to designing a fisetin self-experiment sets out what can realistically be measured and how to avoid fooling yourself with a single before-and-after reading.
Common questions
What is C12FDG?
A fluorescent probe used to detect senescence-associated beta-galactosidase activity in individual cells. The 2024 study used it to count senescent white blood cells [1].
Did fisetin reduce senescent cells in this study?
The C12FDG signal and age-related serum markers were lower in a small subgroup taking fisetin [1]. The abstract gives no subgroup size, dose or control group, so it is an observation, not proof of an effect.
Was this a fisetin trial?
No. It was a study validating a senescence marker in a large cohort of healthy and osteoarthritic patients, with fisetin users noted as a subgroup [1].
Can I order a C12FDG blood test?
Not as a standard clinical test. It is a research method that the authors suggest may become clinically useful [1].
What markers do fisetin trials use instead?
Designs vary. One planned trial of 100 mg a day uses suPAR, a chronic inflammation marker [3], and early studies have looked at circulating secretory phenotype factors [5].
References
- Clinical validation of C12FDG as a marker associated with senescence and osteoarthritic phenotypes. Aging Cell (2024). PMID 38708778
- Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine (2018). PMID 30279143
- Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial. Basic Clin Pharmacol Toxicol (2026). PMID 42633989
- Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. J Am Geriatr Soc (2021). PMID 34375437
- Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review. Clin Interv Aging (2026). PMID 42781074
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.